A Phase 2, randomized, double-blind, placebo controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids.